Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Shigeki Yano"'
Autor:
Takahiro Kinami, Shinsuke Uchikawa, Tomokazu Kawaoka, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kei Amioka, Kensuke Naruto, Kenji Yamaoka, Yasutoshi Fujii, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Shiro Oka
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Aim Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have be
Externí odkaz:
https://doaj.org/article/750b5eb5b5f54de5bfbf22b2506451a0
Autor:
Yusuke Johira, Takashi Nakahara, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, C. Nelson Hayes, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new classification system for fatty liver disease. In this study, we investigated the clinical characteristics of patients with MAFLD-hepatocellular carcino
Externí odkaz:
https://doaj.org/article/571494618e314b039648ca2219373de7
Autor:
Yuki Shirane, Eisuke Murakami, Michio Imamura, Masanari Kosaka, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Tomokazu Kawaoka, Daiki Miki, Masami Yamauchi, Wataru Okamoto, Masataka Tsuge, Keigo Chosa, Kazuo Awai, Hiroshi Aikata, Shiro Oka
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Balloon-occluded retrograde transvenous obliteration (BRTO) is a treatment option for patients with gastric varices (GVs). This study aimed to clarify the clinical significance of portal hypertension estimated by the hepatic venou
Externí odkaz:
https://doaj.org/article/5a5eb080581442ad9a005702ca2d87f1
Autor:
Shigeki Yano, Tomokazu Kawaoka, Shintaro Yamasaki, Yusuke Johira, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Kei Amioka, Kensuke Naruto, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Masataka Tsuge, Yuji Teraoka, Hirotaka Kouno, Shintaro Takaki, Nami Mori, Keiji Tsuji, Shiro Oka
Publikováno v:
Cancers, Vol 15, Iss 22, p 5406 (2023)
A total of 137 HCC patients treated with atezolizumab plus bevacizumab from October 2020 to September 2022 were enrolled. The median overall survival (OS) and progression-free survival (PFS) from the beginning of atezolizumab plus bevacizumab were 21
Externí odkaz:
https://doaj.org/article/aeace0015ad44ea68812d0ef7a8b225f
Autor:
Ryoichi Miura, Tomokazu Kawaoka, Michio Imamura, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Takao Hinoi, Hiroshi Aikata
Publikováno v:
Case Reports in Gastroenterology, Vol 16, Iss 1, Pp 110-115 (2022)
Benign recurrent intrahepatic cholestasis (BRIC) is a group of genetically heterogeneous autosomal recessive liver disorders characterized by recurrent episodes of jaundice and pruritus. BRIC is divided into two groups, BRIC type 1 (BRIC1) and BRIC t
Externí odkaz:
https://doaj.org/article/2d5ab90640d147808d787c9523edc8d7
Autor:
Takahiro Kinami, Kei Amioka, Tomokazu Kawaoka, Shinsuke Uchikawa, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Kenji Yamaoka, Yasutoshi Fujii, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka
Publikováno v:
Cancers, Vol 15, Iss 8, p 2304 (2023)
Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is currently positioned as the first-line therapy for unresectable hepatocellular carcinoma (u-HCC). It may be difficult to decide whether to continue this treatment if radiological res
Externí odkaz:
https://doaj.org/article/02e81fbe33044fab8d5263916c74081f
Autor:
Kenji Yamaoka, Kenichiro Kodama, Tomokazu Kawaoka, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Ryoichi Miura, Shigeki Yano, Serami Murakami, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Shinsuke Uchikawa, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Michio Imamura, Shoichi Takahashi, Akiko Nagao, Kazuaki Chayama, Hiroshi Aikata
Publikováno v:
PLoS ONE, Vol 17, Iss 1, p e0262675 (2022)
Background and aimsThe aim of this study was to investigate the relationship between body composition before lenvatinib treatment and prognosis in patients with hepatocellular carcinoma (HCC). We also assessed the relationship between the rate of cha
Externí odkaz:
https://doaj.org/article/2ce0098d41b643efa18d875a880c4f51
Autor:
Shigeki Yano, Tomoki Kimura, Tomokazu Kawaoka, Takahiro Kinami, Shintaro Yamasaki, Yusuke Johira, Masanari Kosaka, Kei Amioka, Kensuke Naruto, Yuwa Ando, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Michio Imamura, Junichi Hirokawa, Yasushi Nagata, Hiroshi Aikata, Shiro Oka
Publikováno v:
Cancers, Vol 15, Iss 3, p 846 (2023)
The present study retrospectively evaluated the efficacy of stereotactic body radiation therapy (SBRT), including repeated SBRT, for hepatocellular carcinoma. Participants comprised 220 HCC patients treated with SBRT in Hiroshima University Hospital
Externí odkaz:
https://doaj.org/article/93a92a6d7cc1461eba54c27d852e0bdd
Autor:
Yusuke Johira, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Michio Imamura, Kazuhiro Sentani, Naohide Oue, Koji Arihiro, Shintaro Kuroda, Tsuyoshi Kobayashi, Hideki Ohdan, Kazuaki Chayama, Hiroshi Aikata
Publikováno v:
Liver Cancer (2021)
None
Externí odkaz:
https://doaj.org/article/223812ca25cd4aecbe1ae5ead2c18af8
Autor:
Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yumi Kosaka, Shinsuke Uchikawa, Kenichiro Kodama, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Wataru Okamoto, Shoichi Takahashi, Michio Imamura, Hiroshi Aikata
Publikováno v:
Liver Cancer, p 1 (2022)
Introduction Proteinuria is one of the adverse events of atezolizumab plus bevacizumab combination therapy (Atezo+Bev) and can cause interruption in the use of Bev. However, the risk factors for proteinuria in patients with hepatocellular carcinoma (
Externí odkaz:
https://doaj.org/article/c1f11802ee384e018227c7f0659b13e0